International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Dermavant Announces FDA Approval for VTAMA® (Tapinarof) Cream

Dermavant news
Dermavant Sciences announced that VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults, has been approved by the U.S. Food and Drug Administration (FDA). VTAMA® cream provides efficacy over 52 weeks and is well-tolerated on the most sensitive skin areas. This approval makes VTAMA® cream the first and only FDA-approved non-steroid topical medication for adults living with plaque psoriasis. The product is expected to be available beginning June 2022.
Dermavant Sciences, a subsidiary of Roivant Sciences

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

PASI 90 blog post with Dr. Maskin

Access to Biologics in Argentina: Rethinking Time to PASI 90

Blog Post - Psoriasis Hub

IPC Partners with Scientific Education Support to Create New Psoriasis and Psoriatic Arthritis Hub

Blog -Expert Insights-Erica-Alba (1)

Monkeypox Symptoms, Treatment, Prevention, and Impact on Psoriasis Patients

Also Read

PASI 90 blog post with Dr. Maskin
Biologics

Access to Biologics in Argentina: Rethinking Time to PASI 90

Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to acquiring them. This has led IPC Councilor Dr. Matias Maskin to reconsider what success means for psoriasis patients.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.